New acid reducer shows promise in fighting stomach bug

NCT ID NCT07606833

Not yet recruiting Disease control Sponsor: Xuanzhu Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests whether a new acid-reducing drug, anaprazole, works better than the standard drug esomeprazole when used with bismuth and two antibiotics to treat H. pylori infection. About 556 adults in China will take either anaprazole or esomeprazole pills twice daily for 14 days. The main goal is to see if the infection is gone after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anaprazole sodium (a drug that reduces stomach acid) combined with bismuth, amoxicillin, and clarithromycin
What this could lead to: If successful, this could provide a new treatment option for H. pylori infection, potentially improving eradication rates.
What could go wrong: This is a Phase 3 trial, but results may not apply to all populations. The treatment includes antibiotics, which can cause side effects like diarrhea or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HELICOBACTER PYLORI INFECTIONS

Contacts and locations

Locations

Shenzhen Hospital of Southern Medical University

Shenzhen, Guangdong, 518100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.